Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8374 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT03260322Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2017
- Primary completion
- May 2022
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 9
01
Overview
Phase 1, open-label trial of ASP8374 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), bladder cancer and 4 more (17 arms), sponsored by Astellas Pharma. Primary endpoints: Number of Participants with Dose Limiting Toxicities up to 21 Days, Number of Participants with Treatment Emergent Adverse Events and 11 more. Started Sep 2017; status: completed.
02
Drugs
ASP8374
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)bladder cancergastric cancer (GC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03260322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260322.